Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vyvanse lisdexamphetamine: Phase II data

In a double-blind Phase II trial in 52 patients aged 6-12 years, Vyvanse met

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE